Background
Study groups
-
sulfonylurea plus metformin (S+M) for 6 to 12 months
-
the long-acting insulin analogue glargine plus metformin (G+M) for 6 to 12 months
-
a DPP-4 inhibitor plus metformin (D+M) for the past 6 months with a stable anti-diabetic dosage during the past 3 months
C | S + M | G + M | D + M | |
---|---|---|---|---|
Participants
| 20 | 21 | 20 | 19 |
Ratio male/female
| 12/8 | 16/5 | 15/5 | 11/8 |
Age [a]
| 65 ± 1.33 | 64 ± 1.5 | 65 ± 1.58 | 62 ± 1.92 |
Duration of diabetes [a]
| - | 7.9 ± 0.9 | 8.7 ± 1.3 | 6.8 ± 0.9 |
BMI
| 27.1 ± 3.5 | 31.6 ± 2.9 | 30.8 ± 2.9 | 30.2 ± 3.3 |
HbA1c
| 5.6 ± 0.3 | 7.0 ± 0.5 | 7.2 ± 0.2 | 6.6 ± 0.4 |
Basal glucose [mg/dl]
| 100.1 ± 1.5 | 148.0 ± 3.9*** | 146.0 ± 5.1*** | 144.3 ± 5.1*** |
Basal insulin [pmol/l]
| 9.02 ± 0.87 | 17.23 ± 1.63*** | 10.64 ± 1.59°° | 11.70 ± 0.90° |
Basal proinsulin [pmol/l]
| 5.26 ± 0.39 | 16.37 ± 1.45*** | 9.378 ± 0.97*/°°° | 6.878 ± 0.49°°° |
Ethics statement
Serum and plasma analysis
Statistics
Results
Area under the curve | C | S + M | G + M | D + M |
---|---|---|---|---|
TGF-β [ng/ml]
| 7014 | 9689 | 8047 | 4873 |
Glucose [mg/dl]
| 33961 | 51821 | 53402 | 44817 |
Insulin [pmol/l]
| 8268 | 16057 | 8922 | 9493 |
Proinsulin [pmol/l]
| 3165 | 9832 | 6294 | 4523 |